Use of boron for the treatment of leishmaniasis disease

Abstract

A use of boron derivatives as therapeutics in Leishmaniasis disease is provided. The objective relates to the use of sodium perborate tetrahydrate (SPT), which is almost completely effective on Leishmania parasites, but does not show toxicity in healthy cells, in antileishmanial therapy. Considering the methods and techniques which have been developed, the success achieved in the use of SPT and boron derivatives as therapeutics against Leishmaniasis lays the groundwork for treatments of other infectious diseases and enables the design and development of novel preventive and therapeutic methods. There is provided a novel treatment that can be an alternative to conventional drug therapies (such as amphotericin B antimonials) applied in the treatment of Leishmaniasis, which have difficult patient compliance due to side effects.

Dependencies are inferred from the claim text.